Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 8 of 8 for “"Suberoylanilide Hydroxamic Acid (SAHA)"”.
-
The structural requirements of histone deacetylase (hdac) inhibitors: suberoylanilide hydroxamic acid (saha) analogues modified at c3, c6, and c7 positions enhance selectivity
… HDAC inhibitors, including the FDA approved drug suberoylanilide hydroxamic acid (SAHA, Vorinostat), have cleared clinical trials and emerged as anti-cancer drugs. However, SAHA inhibits all of the 11 metal ion-dependent HDAC proteins. Therefore, we synthesized several libraries of small molecule …
-
A Microfabricated Bioimpedance Sensor with Enhanced Sensitivity for Early Breast Cancer Detection
… a silicon substrate was designed and fabricated. Suberoylanilide hydroxamic acid (SAHA), an FDA-approved anti-cancer agent was used to improve the sensitivity of the bioimpedance sensor towards cancer cells by selectively modifying their cytoarchitecture.
-
Nuclear receptor co-repressor actions in bladder cancer
… to NR ligands; treatment with lithocholic acid (LCA - FXR and VDR ligand) led to expression of a cohort of genes consistent with a xenobiotic protective response (ABC transporter proteins, metabolizing enzymes and cell cycle arrest proteins) as assessed by microfluidic quantitative …
-
Novel Micropatterned Substrate for Investigation of Ovarian Cancer Aggregate Formation and Response to Epigenetic Drug Therapy
… of pan-genome epigenetic drugs such as suberoylanilide hydroxamic acid (SAHA). The micropatterned substrate supported cell proliferation, migration, and aggregate formation while maintaining phenotype and viability. Treating aggregates with SAHA maintained cell viability but caused …
-
The synergistic interaction between CD20 monoclonal antibodies and Histone Deacetylase inhibitors in B cell Non Hodgkin’s Lymphoma
… xenograft model, combination treatment<br/>with suberoylanilide hydroxamic acid (SAHA) and Rituximab reduced tumour<br/>growth compared to either agent alone, without discernable toxicity. This<br/>effect appears specific to CD20 since monoclonal antibodies directed to other<br/>surface molecules …
-
Histone deacetylase inhibitors as novel neuroprotective agents in in vitro and in vivo models of Parkinson’s disease
… this reason, the effects of the HDAC-Is, suberoylanilide hydroxamic acid (SAHA) and valproic acid (VPA) were investigated in in vitro and in vivo models of PD. Neither inhibitors protected dopaminergic cell lines, SH-SY5Y and N1E-115, against hydrogen-peroxide (H2O2) and MPP+-induced …
-
Defining The Role of Egfr Acetylation In Cellular Processes: Clinical Implications
… with other anti-cancer agents, we observed that suberoylanilide hydroxamic acid (SAHA, a deacetylase inhibitor) enhanced TKI-induced cancer cell death, which further led us to question whether SAHA-mediated sensitization to TKI was associated with EGFR acetylation. What we know so far is that …
-
Identification of Cell Biomechanical Signatures Using Three Dimensional Isotropic Microstructures
… cells with experimental breast cancer drug, SAHA, on the second generation of substrates, significantly altered the cells morphology, cytoarchitecture and adhesion pattern inside the 3-D microstructures. Third generation of silicon substrates was developed for comprehensive analysis on …